GLP-1 Medications and Sleep Apnea: Evidence for New Treatment

Last Updated: March 2026

The landscape of obstructive sleep apnea (OSA) treatment is undergoing a significant transformation, with GLP-1 medications emerging as a powerful new frontier. In the pivotal SURMOUNT-OSA trial, tirzepatide demonstrated a substantial reduction in the Apnea-Hypopnea Index (AHI) by an average of 27.4 events per hour in participants with moderate-to-severe OSA and obesity who were not receiving positive airway pressure (PAP) therapy, compared to a reduction of 4.8 events per hour with placebo (NEJM, 2024). This groundbreaking evidence paved the way for tirzepatide’s FDA approval in late 2024, marking a pivotal moment in the clinical management of OSA.

Obstructive Sleep Apnea: A Growing Health Crisis

Obstructive sleep apnea is a chronic, progressive condition characterized by recurrent episodes of upper airway collapse during sleep, leading to reduced or complete cessation of airflow despite ongoing breathing efforts. These events, called apneas (complete cessation) and hypopneas (partial reduction), result in fragmented sleep, oxygen desaturation, and increased sympathetic nervous system activity. The immediate consequences include excessive daytime sleepiness, fatigue, and impaired cognitive function.

However, the long-term health implications are far more severe. Untreated OSA is strongly linked to an increased risk of hypertension, type 2 diabetes, cardiovascular disease (including heart attack and stroke), atrial fibrillation, and even premature death. Its prevalence is on the rise, mirroring the global obesity epidemic. Current estimates suggest that over 1 billion people worldwide, aged 30 to 69 years, suffer from OSA, with approximately 425 million having moderate-to-severe disease. Despite its widespread impact, OSA remains significantly underdiagnosed.

The Weight Connection: Obesity as a Primary Driver

The overwhelming majority of OSA cases, particularly moderate-to-severe forms, are directly attributed to obesity. Excess adipose tissue (fat) accumulation around the neck and upper airway structures contributes to the narrowing and collapse of the pharynx during sleep. This mechanical obstruction is exacerbated by other obesity-related factors, including:

• Increased pharyngeal soft tissue volume: Fat deposits directly narrow the airway lumen.
• Reduced lung volume: Obesity can decrease functional residual capacity and lung compliance, impacting upper airway stability.
• Inflammation: Adipose tissue produces pro-inflammatory cytokines, which may contribute to upper airway edema and muscle dysfunction.
• Metabolic dysregulation: Obesity-related insulin resistance and other metabolic changes can further impair respiratory control and muscle tone.

Given this strong correlation, weight loss has long been recognized as a cornerstone of OSA management. Even modest weight reductions can lead to clinically meaningful improvements in AHI and symptom severity. However, achieving and maintaining significant weight loss through conventional diet and exercise alone is notoriously challenging for many individuals, highlighting the unmet need for effective pharmacotherapies.

GLP-1s Enter the Fray: Tirzepatide Leads the Charge

The advent of GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs (like tirzepatide) has revolutionized weight management. Their efficacy in promoting substantial and sustained weight loss has naturally led to their investigation as a treatment for obesity-related comorbidities, including OSA.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, received FDA approval in December 2024 for the treatment of moderate-to-severe OSA in adults with obesity (defined as a BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. This marks the first time a GLP-1 medication has received a specific indication for OSA, signaling a paradigm shift in how the condition can be managed.

The approval was based primarily on the robust findings from the SURMOUNT-OSA program, a pair of randomized, double-blind, placebo-controlled trials: SURMOUNT-OSA Study 1 and SURMOUNT-OSA Study 2.

SURMOUNT-OSA Study 1 (NEJM, 2024): This study enrolled 469 participants with moderate-to-severe OSA and obesity who were not using positive airway pressure (PAP) therapy.

• Tirzepatide group: Patients received 10 or 15 mg of tirzepatide once weekly.
• Placebo group: Patients received placebo once weekly.
• Primary Outcome: Change in AHI from baseline to week 52.

Results demonstrated a significant reduction in AHI in the tirzepatide group compared to placebo:

• Tirzepatide: Mean AHI reduction of 27.4 events per hour.
• Placebo: Mean AHI reduction of 4.8 events per hour.
• This translates to an average 62.8% reduction in AHI with tirzepatide versus 13.6% with placebo.
• Body Weight Reduction: Participants on tirzepatide achieved an average body weight reduction of 18.1% compared to 1.3% with placebo.

SURMOUNT-OSA Study 2 (NEJM, 2024): This study involved 190 participants with moderate-to-severe OSA and obesity who were already using PAP therapy.

• Tirzepatide group: Patients received 10 or 15 mg of tirzepatide once weekly in addition to ongoing PAP therapy.
• Placebo group: Patients received placebo once weekly in addition to ongoing PAP therapy.

Results also showed significant AHI improvement:

• Tirzepatide: Mean AHI reduction of 30.3 events per hour.
• Placebo: Mean AHI reduction of 6.0 events per hour.
• This represents an average 55.0% reduction in AHI with tirzepatide versus 17.0% with placebo in this PAP-adherent population.

The FDA noted that tirzepatide should be used in combination with a reduced-calorie diet and increased physical activity. As Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity, Center for Drug Evaluation and Research at the FDA, stated, “Today’s approval provides a new treatment for people with moderate to severe obstructive sleep apnea and obesity… This drug will provide a needed treatment option for the millions of people who have both conditions.” (FDA, 2024).

Beyond Tirzepatide: Semaglutide and Other GLP-1s

While tirzepatide holds the distinction of the first FDA approval for OSA, other GLP-1 RAs have also shown promising results in improving OSA symptoms, primarily through their potent weight-loss effects.

Semaglutide: Data from various studies and meta-analyses suggest that semaglutide, available as Ozempic/Wegovy, also leads to improvements in OSA. Though not specifically FDA-approved for OSA, its mechanism of action and efficacy in weight reduction align with the observed benefits.

A systematic review and meta-analysis published in Neurology in 2024, examining repositioning GLP-1 drugs for neurologic disease, included studies on OSA. It found that GLP-1 RAs were quite effective, leading to a weight mean difference of –16.6 apnea-hypopnea index (AHI) events per hour (Thiruchelvam et al., 2024). This aggregated data across different GLP-1s reinforces the class effect.

However, the meta-analysis also highlighted a notable downside: GLP-1 RAs were associated with a higher frequency of safety events, with an odds ratio of 1.62 (95% CI, 1.16-2.24) compared with placebo (Thiruchelvam et al., 2024). This underscores the need for careful patient selection and monitoring, similar to their use in diabetes and obesity management.

Other GLP-1s: Liraglutide (Saxenda) has also been studied in smaller cohorts and shown to reduce AHI in individuals with obesity and OSA, correlating with the degree of weight loss achieved. While less potent for weight loss than tirzepatide or semaglutide, it further supports the class-wide benefit.

The general consensus is that any GLP-1 RA that effectively induces significant and sustained weight loss will likely confer benefits for obesity-related OSA. The magnitude of benefit, however, appears to be directly proportional to the amount of weight lost.

How GLP-1s Improve OSA: The Mechanism

The primary mechanism by which GLP-1 medications improve OSA is through substantial and sustained body weight reduction. This weight loss directly addresses the root cause of the airway obstruction:

1. Reduced Adipose Tissue in the Upper Airway: As overall body fat decreases, fat deposits in the neck and around the pharyngeal structures shrink. This increases the cross-sectional area of the upper airway, making it less prone to collapse during sleep.
2. Improved Lung Volumes and Mechanics: Weight loss can improve respiratory mechanics by reducing abdominal and thoracic fat, leading to increased functional residual capacity and better diaphragm function. This can indirectly enhance upper airway stability.
3. Decreased Systemic Inflammation: Obesity is a pro-inflammatory state. Weight loss induced by GLP-1s can reduce systemic inflammation, which may play a role in reducing airway edema and improving muscle tone.
4. Potential Central Effects: While the primary mechanism is mechanical, some research suggests GLP-1 receptors are present in areas of the brain involved in respiratory control. It’s plausible, though not yet definitively proven, that GLP-1s could have some direct effects on central respiratory drive or upper airway muscle activity, independent of weight loss. However, current evidence overwhelmingly points to weight loss as the dominant factor.

Who Benefits Most from GLP-1s for OSA?

GLP-1 medications are a promising treatment for specific patient populations:

• Individuals with Moderate-to-Severe OSA and Obesity/Overweight: The FDA approval for tirzepatide specifically targets